These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

418 related articles for article (PubMed ID: 28040716)

  • 41. The Changing Landscape of Genetic Testing for Inherited Breast Cancer Predisposition.
    Afghahi A; Kurian AW
    Curr Treat Options Oncol; 2017 May; 18(5):27. PubMed ID: 28439798
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Beyond BRCA1 and BRCA2.
    King-Spohn K; Pilarski R
    Curr Probl Cancer; 2014; 38(6):235-48. PubMed ID: 25497410
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Hereditary breast-ovarian cancer: clinical findings and medical management.
    Marshall M; Solomon S
    Plast Surg Nurs; 2007; 27(3):124-7. PubMed ID: 17901820
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Guidance Statement On BRCA1/2 Tumor Testing in Ovarian Cancer Patients.
    Capoluongo E; Ellison G; López-Guerrero JA; Penault-Llorca F; Ligtenberg MJL; Banerjee S; Singer C; Friedman E; Markiefka B; Schirmacher P; Büttner R; van Asperen CJ; Ray-Coquard I; Endris V; Kamel-Reid S; Percival N; Bryce J; Röthlisberger B; Soong R; de Castro DG
    Semin Oncol; 2017 Jun; 44(3):187-197. PubMed ID: 29248130
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Risk assessment and genetic counseling for hereditary breast and ovarian cancer syndromes-Practice resource of the National Society of Genetic Counselors.
    Berliner JL; Cummings SA; Boldt Burnett B; Ricker CN
    J Genet Couns; 2021 Apr; 30(2):342-360. PubMed ID: 33410258
    [TBL] [Abstract][Full Text] [Related]  

  • 46. NCCN Guidelines® Insights: Prostate Cancer, Version 1.2023.
    Schaeffer EM; Srinivas S; Adra N; An Y; Barocas D; Bitting R; Bryce A; Chapin B; Cheng HH; D'Amico AV; Desai N; Dorff T; Eastham JA; Farrington TA; Gao X; Gupta S; Guzzo T; Ippolito JE; Kuettel MR; Lang JM; Lotan T; McKay RR; Morgan T; Netto G; Pow-Sang JM; Reiter R; Roach M; Robin T; Rosenfeld S; Shabsigh A; Spratt D; Teply BA; Tward J; Valicenti R; Wong JK; Berardi RA; Shead DA; Freedman-Cass DA
    J Natl Compr Canc Netw; 2022 Dec; 20(12):1288-1298. PubMed ID: 36509074
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Recommended Extension of Indication Criteria for Genetic Testing of BRCA1 and BRCA2 Mutations in Hereditary Breast and Ovarian Cancer Syndrome].
    Foretová L; Macháčková E; Palácová M; Navrátilová M; Svoboda M; Petráková K
    Klin Onkol; 2016; 29 Suppl 1():S9-13. PubMed ID: 26691937
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Changing landscape of hereditary breast and ovarian cancer germline genetic testing in Australia.
    Petelin L; James PA; Trainer AH
    Intern Med J; 2018 Oct; 48(10):1269-1272. PubMed ID: 30288903
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Current perspectives on recommendations for BRCA genetic testing in ovarian cancer patients.
    Vergote I; Banerjee S; Gerdes AM; van Asperen C; Marth C; Vaz F; Ray-Coquard I; Stoppa-Lyonnet D; Gonzalez-Martin A; Sehouli J; Colombo N
    Eur J Cancer; 2016 Dec; 69():127-134. PubMed ID: 27821315
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Contribution of BRCA1 large genomic rearrangements to early-onset and familial breast/ovarian cancer in Pakistan.
    Rashid MU; Muhammad N; Amin A; Loya A; Hamann U
    Breast Cancer Res Treat; 2017 Jan; 161(2):191-201. PubMed ID: 27826754
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Investigating barriers to genetic counseling and germline mutation testing in women with suspected hereditary breast and ovarian cancer syndrome and Lynch syndrome.
    Shaw J; Bulsara C; Cohen PA; Gryta M; Nichols CB; Schofield L; O'Sullivan S; Pachter N; Hardcastle SJ
    Patient Educ Couns; 2018 May; 101(5):938-944. PubMed ID: 29273311
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Genetic testing for hereditary breast and ovarian cancer and the USPSTF recommendations.
    Wood ME; Garber JE; Isaacs C; Masood S; Bedrosian I; Tung N; Chun J; Schnabel FR; Arun BK;
    Breast J; 2019 Jul; 25(4):575-577. PubMed ID: 31280501
    [No Abstract]   [Full Text] [Related]  

  • 53. NCCN Guidelines® Insights: Myelodysplastic Syndromes, Version 3.2022.
    Greenberg PL; Stone RM; Al-Kali A; Bennett JM; Borate U; Brunner AM; Chai-Ho W; Curtin P; de Castro CM; Deeg HJ; DeZern AE; Dinner S; Foucar C; Gaensler K; Garcia-Manero G; Griffiths EA; Head D; Jonas BA; Keel S; Madanat Y; Maness LJ; Mangan J; McCurdy S; McMahon C; Patel B; Reddy VV; Sallman DA; Shallis R; Shami PJ; Thota S; Varshavsky-Yanovsky AN; Westervelt P; Hollinger E; Shead DA; Hochstetler C
    J Natl Compr Canc Netw; 2022 Feb; 20(2):106-117. PubMed ID: 35130502
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Prediction of Cancer Prevention: From Mammogram Screening to Identification of BRCA1/2 Mutation Carriers in Underserved Populations.
    Robinson LS; Hendrix A; Xie XJ; Yan J; Pirzadeh-Miller S; Pritzlaff M; Read P; Pass S; Euhus D; Ross TS
    EBioMedicine; 2015 Nov; 2(11):1827-33. PubMed ID: 26870808
    [TBL] [Abstract][Full Text] [Related]  

  • 55. NCCN Guidelines® Insights: Distress Management, Version 2.2023.
    Riba MB; Donovan KA; Ahmed K; Andersen B; Braun I; Breitbart WS; Brewer BW; Corbett C; Fann J; Fleishman S; Garcia S; Greenberg DB; Handzo GF; Hoofring LH; Huang CH; Hutchinson S; Johns S; Keller J; Kumar P; Lahijani S; Martin S; Niazi SK; Pailler M; Parnes F; Rao V; Salman J; Scher E; Schuster J; Teply M; Usher A; Valentine AD; Vanderlan J; Lyons MS; McMillian NR; Darlow SD
    J Natl Compr Canc Netw; 2023 May; 21(5):450-457. PubMed ID: 37156476
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Health Care Disparities in Hereditary Ovarian Cancer: Are We Reaching the Underserved Population?
    Randall TC; Armstrong K
    Curr Treat Options Oncol; 2016 Aug; 17(8):39. PubMed ID: 27315065
    [TBL] [Abstract][Full Text] [Related]  

  • 57. NCCN Guidelines Insights: Prostate Cancer, Version 1.2021.
    Schaeffer E; Srinivas S; Antonarakis ES; Armstrong AJ; Bekelman JE; Cheng H; D'Amico AV; Davis BJ; Desai N; Dorff T; Eastham JA; Farrington TA; Gao X; Horwitz EM; Ippolito JE; Kuettel MR; Lang JM; McKay R; McKenney J; Netto G; Penson DF; Pow-Sang JM; Reiter R; Richey S; Roach Iii M; Rosenfeld S; Shabsigh A; Spratt DE; Teply BA; Tward J; Shead DA; Freedman-Cass DA
    J Natl Compr Canc Netw; 2021 Feb; 19(2):134-143. PubMed ID: 33545689
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Experience of risk-reducing salpingo-oophorectomy for a BRCA1 mutation carrier and establishment of a system performing a preventive surgery for hereditary breast and ovarian cancer syndrome in Japan: our challenges for the future.
    Hirasawa A; Masuda K; Akahane T; Tsuruta T; Banno K; Makita K; Susumu N; Jinno H; Kitagawa Y; Sugano K; Kosaki K; Aoki D
    Jpn J Clin Oncol; 2013 May; 43(5):515-9. PubMed ID: 23487443
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Genetic Testing for Hereditary Breast Cancer: The Decision to Decline.
    White VB; Walsh KK; Foss KS; Amacker-North L; Lenarcic S; McNeely L; White RL
    Am Surg; 2018 Jan; 84(1):154-160. PubMed ID: 29428045
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The changing landscape of genetic testing for hereditary breast and ovarian cancer.
    Bellcross CA
    Curr Probl Cancer; 2014; 38(6):209-15. PubMed ID: 25497408
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.